| 001 | 157227 | ||
| 005 | 20240917143639.0 | ||
| 024 | 7 | _ | |a 10.1038/s41375-020-0948-0 |2 doi |
| 024 | 7 | _ | |a pmid:32694619 |2 pmid |
| 024 | 7 | _ | |a 0887-6924 |2 ISSN |
| 024 | 7 | _ | |a 1476-5551 |2 ISSN |
| 024 | 7 | _ | |a altmetric:86233320 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-01497 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Goldschmidt, Hartmut |b 0 |
| 245 | _ | _ | |a Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. |
| 260 | _ | _ | |a London |c 2021 |b Springer Nature |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1726576585_15212 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Apr;35(4):1134-1144 |
| 520 | _ | _ | |a The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65-1.16; p = 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52-1.28; p = 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and did not significantly prolong PFS and OS on ITT analysis while patients who received sHDCT/ASCT may have benefitted. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Baertsch, Marc-Andrea |0 0000-0002-4000-6904 |b 1 |
| 700 | 1 | _ | |a Schlenzka, Jana |b 2 |
| 700 | 1 | _ | |a Becker, Natalia |0 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0 |b 3 |
| 700 | 1 | _ | |a Habermehl, Christina |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 5 |u dkfz |
| 700 | 1 | _ | |a Raab, Marc-Steffen |0 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3 |b 6 |u dkfz |
| 700 | 1 | _ | |a Hillengass, Jens |b 7 |
| 700 | 1 | _ | |a Sauer, Sandra |b 8 |
| 700 | 1 | _ | |a Müller-Tidow, Carsten |0 0000-0002-7166-5232 |b 9 |
| 700 | 1 | _ | |a Luntz, Steffen |b 10 |
| 700 | 1 | _ | |a Jauch, Anna |b 11 |
| 700 | 1 | _ | |a Hose, Dirk |b 12 |
| 700 | 1 | _ | |a Seckinger, Anja |b 13 |
| 700 | 1 | _ | |a Brossart, Peter |b 14 |
| 700 | 1 | _ | |a Goerner, Martin |b 15 |
| 700 | 1 | _ | |a Klein, Stefan |b 16 |
| 700 | 1 | _ | |a Schmidt-Hieber, Martin |b 17 |
| 700 | 1 | _ | |a Reimer, Peter |b 18 |
| 700 | 1 | _ | |a Graeven, Ullrich |b 19 |
| 700 | 1 | _ | |a Fenk, Roland |b 20 |
| 700 | 1 | _ | |a Haenel, Mathias |b 21 |
| 700 | 1 | _ | |a Martin, Hans |b 22 |
| 700 | 1 | _ | |a Lindemann, Hans W |b 23 |
| 700 | 1 | _ | |a Scheid, Christoph |b 24 |
| 700 | 1 | _ | |a Nogai, Axel |b 25 |
| 700 | 1 | _ | |a Salwender, Hans |b 26 |
| 700 | 1 | _ | |a Noppeney, Richard |b 27 |
| 700 | 1 | _ | |a Besemer, Britta |b 28 |
| 700 | 1 | _ | |a Weisel, Katja |b 29 |
| 700 | 1 | _ | |a Group, German Myeloma Multicenter |b 30 |e Collaboration Author |
| 773 | _ | _ | |a 10.1038/s41375-020-0948-0 |0 PERI:(DE-600)2008023-2 |n 4 |p 1134-1144 |t Leukemia |v 35 |y 2021 |x 1476-5551 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:157227 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-319H |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Addenda |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-01-10 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b LEUKEMIA : 2018 |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-01-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2020-01-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2020-01-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b LEUKEMIA : 2018 |d 2020-01-10 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A360-20160331 |k A360 |l KKE Mol. Hämatologie/Onkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)A360-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::